Study Published in European Radiology Further Supports the Use of Hologic's Breast Tomosynthesis in Cancer Screening in

 Study Published in European Radiology Further Supports the Use of Hologic's
   Breast Tomosynthesis in Cancer Screening in Practices Using Double Reads

  PR Newswire

  BEDFORD, Massachusetts, April 17, 2013

- Breast cancer screening with tomosynthesis finds cancers missed by 2D
screening alone utilizing the double read with arbitration approach used in
many countries of the world

BEDFORD, Massachusetts, April 17, 2013 /PRNewswire/ -- Hologic, Inc. (Hologic
or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier
of premium diagnostics, medical imaging systems and surgical products
dedicated to serving the healthcare needs of women, today announced that a new
study published online in advance of print by European Radiology supports the
use of breast tomosynthesis in combination with 2-dimensional (2D) imaging in
breast cancer screening programs using independent double reading with

The study, "Prospective Trial Comparing Full-field Digital Mammography (FFDM)
versus Combined FFDM and Tomosynthesis in a Population-based Screening
Programme Using Independent Double Reading with Arbitration," was led by Per
Skaane, M.D., Ph.D. of Oslo University Hospital Ullevaal. [1] The analysis
included a total of 12,621 screening examinations of women participating in
the Oslo Tomosynthesis Screening Trial. In double reading, two radiologists
independently read the same case and if the radiologists disagree on the
diagnosis, there is an arbitration or consensus meeting where the final
diagnosis of the case is decided. Double reading has been shown to increase
cancer detection and is the standard method used for interpretation of
mammograms for most countries outside of the U.S. with organized
population-based screening programs. This study compares double reading of 2D
mammography with double reading of 2D mammography plus tomosynthesis.

The researchers used Hologic's breast tomosynthesis cancer screening
technology and found:

  *Tomosynthesis-based screening was successfully implemented in a large
    prospective screening trial.
  *Double reading of tomosynthesis-based examinations significantly reduced
    false-positive interpretations. False-positive interpretations were
    decreased by 18% using 2D plus tomosynthesis.
  *Double reading of tomosynthesis-based examinations significantly increased
    the detection of breast cancers by approximately 30%. The detection of
    invasive cancers was increased by approximately 40%.

"It is very encouraging, though not surprising, to see confirmation of the
strong benefits our tomosynthesis technology can bring to users across
different clinical environments," said Peter Soltani, Hologic's Senior Vice
President and General Manager of Breast Health. "The Oslo data clearly
indicates that double reading of 2D plus tomosynthesis imaging results in a
large increase in the detection of invasive cancers and a reduction in false
positives when compared with 2D double readings alone. This study reinforces a
previous study measuring the benefits of tomosynthesis for a single reader and
demonstrates that tomosynthesis provides major improvements in breast cancer
screening for both single and double-reading screening methods. We believe
that Hologic's breast tomosynthesis technology can make significant inroads in
overcoming the limitations of conventional mammography, namely missed cancers
and unnecessary recalls, and we expect the results of this study to further
support the adoption of our tomosynthesis technology."

The European Radiology paper is the first peer-reviewed publication comparing
the performance of double reading of 2D exams with double reading of 2D plus
tomosynthesis imaging in a large prospective clinical trial.

Hologic's breast tomosynthesis technology has been approved for use for breast
cancer screening and diagnosis in countries recognizing the CE mark since
2008. It was approved for use in the U.S. in February, 2011. Hologic systems
are now in use in 48 states in the U.S. and over 50 countries.

For more information about Hologic's breast tomosynthesis technology, please
visit (for healthcare providers) and (for

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium
diagnostic products, medical imaging systems, and surgical products. The
Company operates four core business units focused on diagnostics, breast
health, GYN surgical and skeletal health. With a comprehensive suite of
technologies and a robust research and development program, Hologic is
committed to improving lives. The Company is headquartered in Massachusetts.

Hologic is a trademark and/or registered trademark of Hologic, Inc., and/or
its subsidiaries in the United States and/or other countries.

Forward Looking Statement Disclaimer.

This News Release may contain forward-looking information that involves risks
and uncertainties, including statements about the use of Hologic digital
mammography systems. There can be no assurance the systems will achieve the
benefits described herein and that such benefits will be replicated in any
particular manner with respect to an individual patient as the actual effect
of the use of the systems can only be determined on a case-by-case basis
depending on the particular circumstances and patient in question. Hologic
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to the data or statements presented herein to reflect any
change in the Company's expectations or any change in events, conditions or
circumstances on which any such data or statements are based.

Marianne McMorrow                   Pat Hall
Global PR and Advertising Publicist Director of Corporate Communications
Hologic, Inc.                       Hologic, Inc.
Tel:+1 781 999 7723                 Tel: +1 781 999-7463

[1] Skaane P, Bandos A I, Gullien R, Eben E B, Ekseth U, Haakenaasen U, Izadi
M, Jebsen I N, Jahr G, Krager M, Hofvind S. Prospective trial comparing
full-field digital mammography (FFDM) versus combined FFDM and tomosynthesis
in a population-based screening programme using independent double reading
with arbitration. European Radiology. Published on line in advance of print,
April, 2013.

Press spacebar to pause and continue. Press esc to stop.